You Assigned the Marketing KPI. Did You Assign Control Over What Drives It?
Why B2B digital health companies need to connect marketing accountability with the processes, decisions and dependencies that actually produce performance.
Your content-assisted pipeline is down 25%. Marketing owns the KPI, so the next step seems obvious: find out what Marketing needs to change.
Perhaps the content strategy needs adjusting. Perhaps the calls to action are weak. Maybe the team needs more bottom-of-funnel content or a different distribution mix.
All reasonable possibilities. But there is a problem with starting there: the fact that Marketing owns the number does not mean Marketing caused the movement in it.
In a B2B digital health company, a single marketing KPI can sit downstream of decisions made by Marketing, Clinical, Product, Growth, RevOps and Sales. One person may be accountable for the result while several teams influence how that result is produced.
That is not inherently a problem. Cross-functional dependencies are normal. The problem begins when a company assigns responsibility for a metric without being equally clear about the variables behind it, who can change them and what happens when those variables sit somewhere else.
Because a KPI can tell you that performance changed. It cannot tell you, on its own, where to intervene.
And if the intervention is wrong, the consequences extend beyond the dashboard. Budget moves. Strategy changes. People are evaluated. Channels are deprioritized. New work gets commissioned. A company can make a perfectly rational investment based on the wrong diagnosis.
A KPI tells you what happened. It doesn’t tell you why.
Imagine a B2B mental health company selling a digital intervention to employers. Marketing tracks qualified demo requests generated through content, and that number has been declining for two months.
The obvious interpretation is that content is converting less effectively. The team starts reviewing high-intent pages, calls to action and editorial topics.
Before changing anything, however, it looks more closely at what happened around the same time.
Traffic to the relevant pages has remained relatively stable. Engagement has not deteriorated significantly. But the company recently repositioned the product from a broad employee wellbeing benefit toward a more clinical mental health solution.
That positioning change affects more than the website copy. It changes the decision the buyer is being asked to make.
An HR or Benefits leader evaluating a wellbeing benefit may primarily need to understand employee relevance, engagement, implementation and cost. A buyer considering a clinical mental health solution may need stronger evidence, clearer information about appropriate use, more confidence in clinical governance and a better understanding of how the solution fits alongside existing care.
The content may still be attracting relevant people. The content itself may still be good. But the burden of proof required before those people request a demo has changed.
The dashboard says that content conversion declined. The underlying commercial problem may be that the existing buyer journey no longer creates enough confidence for the decision being asked of the buyer.
Those diagnoses lead to very different interventions. One sends the team toward new articles, landing pages and CTAs. The other may require changes to positioning, evidence translation, implementation information or the way the product is presented before a sales conversation.
The KPI is accurate in both cases. What changes is the explanation.
This is the first limit of KPI ownership: owning a metric is not the same as owning every cause behind it.
Accountability only works when there is enough control to act
Now imagine that the same company assigns its Content Marketing Manager responsibility for increasing qualified demo requests from the newsletter. The responsibility sounds clear. The manager can choose topics, develop the editorial strategy, change the copy and test different ways of presenting the product.
But subscriber acquisition sits with Growth. Segmentation requires Marketing Ops. Clinical decides what the evidence allows the company to claim. Product controls significant changes to the landing page. RevOps owns attribution. Sales determines what happens once a lead enters the CRM.
None of this means the Content Marketing Manager should own Growth, Clinical, Product, RevOps and Sales. That would simply replace one accountability problem with another.
It does mean that “owns newsletter-generated demos” is incomplete as an operating instruction.
Can the manager change the offer? Can they create new audience segments? Can they request a landing-page experiment and reasonably expect it to happen? Can they see historical conversion data? Can they determine whether the quality of new subscribers has changed? If an experiment requires more capacity, can they deprioritize something else?
These questions are not administrative details around the KPI. They determine how much power the responsible person actually has to influence it.
A useful distinction appears here between responsibility and control. Responsibility tells us who is expected to improve the result. Control tells us which levers that person can actually move. Clear processes connect the two.
This is often where I start when looking at content performance in a B2B health company: not with the editorial calendar, but with the metric the team is expected to move and the decisions, variables and dependencies sitting behind it.
Dependencies don’t need to be owned. They need to be explicit.
This distinction becomes particularly important in digital mental health, where legitimate clinical, product and commercial boundaries shape what Marketing can do.
Consider an evidence-led campaign aimed at HR and Benefits leaders. Marketing owns the campaign and is accountable for qualified demo requests. One of the campaign’s central assets discusses research showing improvement in a validated mental health outcome.
Marketing may want to make the finding easier for a buyer to understand. Clinical, however, determines whether the evidence supports a broad statement such as “reduces anxiety” or a narrower claim about participants reporting lower scores on a particular measure after a defined period.
Marketing should not independently override that judgment simply because a broader claim might convert better. But this also means Clinical controls a variable that can materially affect how the proposition is communicated.
That dependency needs more than the label “Clinical approval.” Marketing needs to know which claims are already established, what can be adapted without changing their meaning, what requires new review and who makes the final decision when new evidence changes what the company can responsibly say.
Now consider a different point in the buyer journey. The campaign generates qualified traffic and buyers find the evidence credible, but Sales repeatedly hears the same question: how does this solution fit alongside our existing EAP or mental health care pathway?
The answer may depend on Product, Partnerships or implementation teams. Marketing does not need to own those decisions. Yet if it is accountable for conversion, it needs a reliable way to understand product changes that affect the buying case and translate them into useful buyer information.
A dependency can also change the metric itself. Suppose Sales decides that organizations below a particular number of covered lives no longer count as qualified opportunities. Content-assisted pipeline subsequently falls. The marketing activity may be generating exactly the same level of interest from exactly the same audience, but the definition of a commercially valuable lead has changed.
Or RevOps changes the attribution window for content-assisted pipeline. The dashboard moves again, even though buyer behaviour has not.
These are different kinds of dependency, but they share an important characteristic: they can change either the result or what the result means.
That is why the KPI owner does not need ownership of every variable. They need clarity about their relationship to the material ones. Some variables are directly owned and can be changed without cross-functional intervention. Others are shared and require another function to act. Still others are primarily observed: search demand, procurement cycles or market conditions cannot be controlled, but they matter when performance is interpreted.
The important question is not “Can Marketing control everything that affects this KPI?” It cannot. The better question is:
Does Marketing know what it controls, what it shares with others and what it needs to observe before deciding why the number moved?
A dependency needs a route for action
Even that is not enough. An organization can have beautifully documented ownership and still make optimization painfully difficult.
Everyone knows that Clinical owns evidence claims. Everyone knows Product owns implementation. Everyone knows RevOps owns attribution. The org chart is not the problem.
The problem appears when Marketing identifies something affecting its KPI and nobody has defined what happens next.
Suppose an evidence page is attracting qualified visitors, but few progress further into the buyer journey. Marketing combines analytics with Sales feedback and identifies a plausible reason: the page explains the research well but does not answer the implementation questions buyers are raising before they will consider the product.
Marketing now needs information from Product and perhaps new language reviewed by Clinical. If there is no established route for obtaining either, the insight can sit unresolved while the KPI owner remains accountable for conversion.
Clear process ownership should remove that uncertainty. Who can provide the implementation answer? Who decides whether it can be communicated externally? When does Clinical need to be involved? What can Marketing change independently? If two teams have conflicting priorities, who decides whether this issue is important enough to act on now?
This is where decision rights become more important than a list of responsibilities.
In a digital health company, there will always be legitimate tensions between commercial clarity, scientific accuracy, product reality and what Sales needs to move a buyer forward. A clear process does not remove those tensions. It prevents the company from renegotiating how to resolve them every time they appear.
For the KPI owner, that creates a practical learning loop: observe what is happening, develop a plausible diagnosis, change a relevant variable, measure the result and use what was learned to decide what happens next.
If the responsible person can see the problem but has no predictable route for changing the variables involved, they do not fully own that optimization process. They own a number they are expected to improve.
Poor process clarity can turn analytics into the wrong investment
This is where what looks like an operational issue becomes a commercial one.
Imagine qualified demos from content fall by 20%. The company concludes that existing content is not sufficiently conversion-focused and invests in a new set of decision-stage assets. The real change, however, was that a new acquisition source introduced a larger proportion of lower-intent visitors.
Or newsletter-generated demos fall, prompting a complete editorial rethink. Later, the team discovers that deliverability deteriorated while engagement among subscribers who actually received the newsletter remained healthy.
A digital mental health company might see weaker conversion from an evidence page and conclude that the research needs to be presented more persuasively. The real obstacle may be that buyers understand the evidence perfectly well but cannot determine how the product fits into their existing clinical pathway.
In each case, the metric captured something real. The error happened in moving from observation to explanation.
That distinction matters because companies rarely stop at explanation. They intervene. They commission content, change positioning, shift budgets, redesign pages, add tools, stop campaigns or evaluate someone’s performance.
The chain is therefore larger than the dashboard: KPI movement informs attribution; attribution informs diagnosis; diagnosis determines intervention; intervention directs investment.
A weak diagnosis early in that chain can make every decision after it look rational while still sending resources toward the wrong problem.
There is another difficulty. The variables easiest to measure are often the easiest to blame. CTR is visible; buyer confidence is not. Landing-page conversion is visible; whether a buyer has enough evidence to secure internal approval is harder to observe. Publishing frequency is easy to count; ambiguity in the company’s positioning is not.
Good marketing measurement therefore requires more than monitoring what is visible. It requires understanding which factors are materially capable of producing the result.
Otherwise, dashboards can create precision without producing much diagnostic clarity.
When the conditions change, the KPI changes with them
There is another way accountability becomes distorted: the target remains stable while the conditions under which someone is expected to achieve it change.
Suppose a marketing lead begins the quarter with a target for increasing organic qualified pipeline. The strategy, expected output and available capacity are agreed.
A month later, the company adds a major event campaign. Then executive thought leadership becomes a priority. Sales needs urgent collateral. A new newsletter initiative is added.
The original KPI remains untouched, but the resources available to influence it have changed substantially.
If the target is missed at the end of the quarter, what exactly has been tested? Was the organic strategy ineffective, or was it never executed under the conditions assumed when the target was established?
The same problem appears when the change is not about capacity. Clinical may introduce new claim guidance that limits language previously used in acquisition campaigns. Product may reposition the solution and increase the amount of information a buyer needs before converting. Sales may change qualification criteria. RevOps may alter attribution.
In each case, the dashboard can make performance before and after the change look directly comparable even when the underlying conditions are not.
This matters because companies naturally want metrics to create continuity. But continuity in the number does not guarantee continuity in what produced it.
When resources, priorities, decision rights, product conditions or measurement rules change materially, that change needs to become part of how subsequent performance is interpreted.
Historical context matters for the same reason. A marketer asked to “grow” a KPI needs to understand the baseline, previous interventions, seasonality and significant changes in how the metric has been calculated.
Otherwise, the company risks attributing normal variation to a new strategy, interpreting a changed definition as a performance problem, or judging a strategy that was never given the conditions required to execute.
Design accountability before the number moves
It is much easier to create explanations after seeing the result. If pipeline rises during a quarter when Marketing changes the content strategy, SEO rankings improve, Product launches a new feature and Sales introduces a different outreach process, several teams can plausibly claim contribution. If pipeline falls, the same ambiguity allows several equally plausible explanations.
This does not require poor management or internal politics. It is simply difficult to reason about causality when the important variables are identified only after the outcome is known. The more useful work happens earlier.
When an important marketing KPI is assigned, trace it backwards far enough to understand the few variables most capable of moving it. Establish which of those the responsible person can change directly, which require another owner and which need to be monitored because they can affect interpretation.
For the shared variables, make the route for action clear. If Marketing identifies a clinical-claim problem, there should already be a way to resolve it. If Product makes a change that materially affects the buying proposition, Marketing should not discover it through falling conversion. If Sales changes qualification criteria, the person accountable for marketing-generated pipeline should know before the next dashboard makes performance appear to have deteriorated.
Then protect the ability to learn. The KPI owner needs enough access to historical data to establish a credible baseline, enough authority to run meaningful interventions, and enough continuity in priorities to understand what those interventions actually produced.
This does not require elaborate governance around every metric. It requires proportionate clarity around the metrics important enough to drive decisions, budgets and performance expectations.
A clear KPI needs clear conditions for acting on it
Assigning someone a KPI is useful. It establishes what outcome matters and who is expected to pay attention to it. But meaningful accountability requires more.
The person responsible for the result needs sufficient control over the variables they are expected to optimize, clear processes for the variables they share with other teams, and visibility when something outside their control materially changes either the result or what the result means.
That does not eliminate uncertainty from marketing. Nor does it make one person responsible for every dependency.
It makes the uncertainty easier to diagnose.
When the number moves, the organization is better equipped to distinguish a content problem from a positioning problem, an acquisition problem from a conversion problem, a performance change from a measurement change, and an ineffective strategy from one whose operating conditions changed halfway through execution.
That distinction matters because marketing metrics are not useful merely because they can be measured. Their value lies in helping a company decide what to do next.
The purpose of clear marketing processes is not to make accountability heavier. It is to make performance more interpretable—and the next investment more informed.
If your B2B health marketing has clear growth targets but less clarity around the processes, dependencies and decisions behind them, this is something I examine in my consulting work. I help teams identify where content, evidence, buyer needs and commercial processes have become disconnected, so they can see what actually needs to change before adding more activity or investment.
